The last three months have been a little more challenging for Alnylam Pharmaceuticals ( ALNY ), with slowing sales at a key rival raising concerns about the overall health of the critical transthyretin amyloidosis (or TTR) space, particularly withAnalyst’s Disclosure:I/we have a beneficial long position in the shares of ALNY, RHHBY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than f ...